Recent compounded semaglutide China headlines trace back to two Chinese ingredient factories placed on an FDA border-hold list. A U.S. pharmacy mixes the finished prescription, even when its raw powder comes from abroad.
Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy. A compounded medication is different from an FDA-approved product: the formulation offered here is not FDA-approved.
Public FDA records do not link either Chinese factory to specific U.S. pharmacies or to Promise. Still, the news shows why batch paperwork and a state-licensed pharmacy matter.
What the compounded semaglutide China alert covers
As of October 17, 2026, the day this article was written, FDA Import Alert 66-40 lists two Chinese plants added in autumn 2026. This alert lets border staff hold drugs from plants that failed federal manufacturing standards. Its two Red List entries, dated September 19, 2026 and October 1, 2026, cover all drugs from both plants.
The alert page does not name semaglutide or print inspection notes. On October 15, 2026, Bloomberg reported on FDA inspection records for both plants. An August 2026 inspection at the first plant reported "black mould," "gross contamination," and "significant insect activity" inside.
In NewsNation's October 16, 2026 report on Bloomberg's findings, workers hid lab papers by "stuffing them into lockers" during the visit. Staff were also seen to "pour product samples down sinks". At the second plant in September 2026, Bloomberg reported an "approval seal" was put on untested outside ingredients.
A September 23, 2026 parent-company filing confirmed the August inspection, an August 27 Form 483 (an inspection-observation report), and a September 17 reply. It reported a U.S. peptide-shipment pause and no warning letter received as of September 22.
| Date in 2026 | Event | Source |
|---|---|---|
| July 30 | Lab study on compounded semaglutide impurities published | Pharmaceutical Research |
| August 20–27 | First plant inspected; eight-observation Form 483 issued | Company filing (Sept 23) |
| September 19 | First plant added to FDA Import Alert 66-40 | FDA Import Alert 66-40 |
| October 1 | Second plant added to FDA Import Alert 66-40 | FDA Import Alert 66-40 |
| October 15–16 | Bloomberg and NewsNation report inspection details | Syndicated news reports |
Where compounded semaglutide comes from under federal law
The raw powder and the finished prescription have separate supply chains. An active pharmaceutical ingredient, or API (the raw drug powder), comes from chemical plants. A U.S. pharmacy buys that powder and prepares each prescription.
U.S. pharmacy preparation does not prove U.S. manufacture of the raw ingredient. In FDA Import Alert 66-80, updated October 9, 2026, FDA notes GLP-1 ingredients came from suppliers "including China, India, and Europe" during shortages. See the GLP-1 green list for how Alert 66-80 screens foreign ingredient suppliers.
Under Section 503A of the FD&C Act, bulk ingredients need an FDA-registered manufacturer, which may be foreign, and valid certificates of analysis. They must meet any applicable monograph, a public ingredient-quality standard.
A certificate of analysis is a batch lab report covering identity, strength, and purity. In its facility registration guide, FDA notes "the agency does not approve manufacturing facilities independently," so registration is not approval. Under FDA import alert rules, FDA can "detain future shipments of the product without having to test or otherwise physically examine it" first.
How active ingredient rules apply to tirzepatide and GLP-1 testing
Bloomberg's reporting connected the inspected plants to both semaglutide and tirzepatide ingredients. Tirzepatide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy. Compounded tirzepatide is different from an FDA-approved product: the formulation offered here is not FDA-approved.
In its April 1, 2026 policy update, FDA notes that neither semaglutide nor tirzepatide is on its drug shortage list. Neither drug appears on the 503B bulks list for FDA-registered outsourcing facilities. Section 503A restricts regularly making essentially copies unless a prescriber documents a change that "produces a significant difference" for an identified patient.
Adding vitamin B12 does not automatically satisfy that rule. Compounded drugs lack premarket review, though a licensed provider may still prescribe — that decision is between you and your doctor. Section 503A allows compounding "in limited quantities before the receipt of a valid prescription order for such individual patient" based on past orders.
Ingredient manufacturers must follow current good manufacturing practice, the federal rules for consistent drug production and quality control. Drugs that meet all Section 503A conditions, the federal framework for traditional compounding, are exempt from those particular rules; other requirements still apply. In its December 2023 Chapter 797 FAQs, USP separates Chapter 795 nonsterile work from USP Chapter 797 sterile compounding.
An ingredient certificate does not prove that a finished vial is sterile. Required sterility and bacterial-toxin checks depend on the preparation category and its beyond-use date, the deadline for using the preparation. Batches released before test results finish need a recall plan to "Immediately notify the prescriber" if a sample fails.
What lab studies and the October 2026 alert do not mean
Import Alert 66-40 does not ban all Chinese ingredients or prove every compounded vial is contaminated. Public records do not estimate China's ingredient share, name U.S. pharmacies using either plant, or link either plant to Promise. They also do not show that "black mould" reached finished vials or harmed patients.
A July 30, 2026 Pharmaceutical Research study tested 13 injectable compounded semaglutide products, detecting 44 impurities in eight. Separate blood-cell tests in 15 healthy donors showed immune-cell presentation of synthesized impurity fragments.
The authors noted this lab test "has not been tested clinically" in patients. It "cannot determine if an immunogenic reaction will happen in a patient," meaning an unwanted immune response. Novo Nordisk funded the study, and all authors worked for the company and held its stock.
A November 2024 study in JMIR ordered semaglutide from six online sellers that did not require a prescription. Three pen orders were nondelivery scams, while three delivered vials held "+28.56% to +38.69%" more drug than labeled. The Hungarian Scientific Research Fund supported the work, and two authors worked for S-3 Research LLC.
All three vials were "devoid of viable microorganisms at the time of testing," meaning no live germs grew. One vial showed elevated bacterial endotoxin at "8.9511 EU/mg" in lab testing.
Enough bloodstream endotoxin "can cause harmful effects such as fever and septic shock and can be fatal in the most severe cases," USP notes. Those three no-prescription sellers do not represent licensed U.S. pharmacies.
How a prescribed pharmacy route differs — and what to watch next
In its compounding Q&A, FDA notes that "Compounded drugs are not FDA-approved" and do not undergo premarket review. State boards of pharmacy oversee day-to-day operations at state-licensed 503A pharmacies. FDA warns that "Compounding drugs under insanitary conditions can put patients at risk and lead to widespread patient harm" as well.
In its October 1, 2026 GLP-1 update, FDA states that patients should get a doctor's prescription and fill it at a state-licensed pharmacy. FDA notes that "Some of the adverse events are serious" in general safety reports and warns about fake pharmacy labels. FDA also recommends that patients "not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration" after shipping.
See how compounded medications are made and compounded semaglutide in 2026 for how a traceable prescription works. Patients can ask which state licenses the pharmacy, whether the ingredient maker is FDA-registered with a valid analysis certificate, and which lot tests ran. At Promise, a licensed provider reviews every request, and not everyone qualifies.
As of October 17, 2026, the day this article was written, searches of FDA records had not located public 2026 Form 483 texts. Those searches also had not located public warning letters for these inspections.
Watch for published inspection reports, Alert 66-40 updates, or any recall naming specific pharmacy lots. As FDA says, "Talk to your doctor if you have questions about your medicines," or report problems to FDA MedWatch.
